Spots Global Cancer Trial Database for tivozanib
Every month we try and update this database with for tivozanib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | NCT01076010 | Advanced Renal ... | Tivozanib Sorafenib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors | NCT01306630 | Advanced Solid ... Locally Advance... | tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas | NCT01782313 | Recurrent Adult... Stage III Adult... Stage IV Adult ... | tivozanib laboratory biom... | 18 Years - | Northwestern University | |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas | NCT01782313 | Recurrent Adult... Stage III Adult... Stage IV Adult ... | tivozanib laboratory biom... | 18 Years - | Northwestern University | |
| Tivozanib + Gemcitabine in Metastatic RCC | NCT01834183 | Renal Cell Carc... | Tivozanib Gemcitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Tivozanib + Enzalutamide in Adv Prostate Cancer | NCT01885949 | Prostate Cancer | Tivozanib Enzalutamide | 18 Years - | Massachusetts General Hospital | |
| Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers | NCT00660153 | Colorectal Canc... Gastrointestina... | Tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | NCT03136627 | Carcinoma, Rena... | Tivozanib Nivolumab | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors | NCT01210846 | Advanced Solid ... | tivozanib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | NCT00717340 | Metastatic Brea... | tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | NCT00717340 | Metastatic Brea... | tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | NCT06053658 | Renal Cell Carc... | Tivozanib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | NCT06053658 | Renal Cell Carc... | Tivozanib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | NCT01478594 | Colorectal Canc... | Tivozanib Bevacizumab mFOLFOX6 | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | NCT05000294 | Bile Duct Cance... Gall Bladder Ca... Breast Cancer Neuroendocrine ... Ovarian Cancer Pancreatic Aden... Soft Tissue Sar... Vulvar Cancer Prostate Cancer | Atezolizumab Tivozanib | 18 Years - 99 Years | University of Florida | |
| A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | NCT00502307 | Carcinoma, Rena... | Tivozanib (AV-9... Placebo compara... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | NCT01297244 | Renal Cell Carc... | Tivozanib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma | NCT00563147 | Renal Cell Carc... | tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC) | NCT00826878 | Carcinoma, Non-... | Tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Tivozanib for Recurrent Glioblastoma | NCT01846871 | Glioblastoma | Tivozanib | 18 Years - | Massachusetts General Hospital | |
| Tivozanib + Gemcitabine in Metastatic RCC | NCT01834183 | Renal Cell Carc... | Tivozanib Gemcitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | NCT04645160 | Cholangiocarcin... Bile Duct Neopl... Biliary Tract M... | Tivozanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | NCT04987203 | Renal Cell Carc... | Tivozanib Nivolumab | 18 Years - 130 Years | AVEO Pharmaceuticals, Inc. | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | NCT01769885 | Stage II Renal ... Stage III Renal... | tivozanib therapeutic con... | 18 Years - | Roswell Park Cancer Institute | |
| A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | NCT00717340 | Metastatic Brea... | tivozanib (AV-9... | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | NCT01297244 | Renal Cell Carc... | Tivozanib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Tivozanib + Enzalutamide in Adv Prostate Cancer | NCT01885949 | Prostate Cancer | Tivozanib Enzalutamide | 18 Years - | Massachusetts General Hospital | |
| Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | NCT01807156 | Hepatocellular ... | Tivozanib | 18 Years - | Emory University | |
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | NCT04987203 | Renal Cell Carc... | Tivozanib Nivolumab | 18 Years - 130 Years | AVEO Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
